Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Practice Essentials
Epilepsy is defined as a brain disorder characterized by an enduring predisposition to generate epileptic seizures and by the neurobiologic, cognitive, psychological, and social consequences of this condition.[1]
Diagnosis
The diagnosis of epileptic seizures is made by analyzing the patient's detailed clinical history and by performing ancillary tests for confirmation. Physical examination helps in the diagnosis of specific epileptic syndromes that cause abnormal findings, such as dermatologic abnormalities (eg, patients with intractable generalized tonic-clonic seizures for years are likely to have injuries requiring stitches). Testing Potentially useful laboratory tests for patients with suspected epileptic seizures include the following: Prolactin levels obtained shortly after a seizure to assess the etiology (epileptic vs nonepileptic) of a spell; levels are typically elevated 3- or 4-fold and more likely to occur with generalized tonic-clonic seizures than with other seizure types; however, the considerable variability of prolactin levels has precluded their routine clinical use Serum levels of anticonvulsant agents to determine baseline levels, potential toxicity, lack of efficacy, treatment noncompliance, and/or autoinduction or pharmacokinetic change CSF examination in patients with obtundation or in patients in whom meningitis or encephalitis is suspected Imaging studies The following 2 imaging studies must be performed after a seizure: Neuroimaging evaluation (eg, MRI, CT scanning) EEG The clinical diagnosis can be confirmed by abnormalities on the interictal EEG, but these abnormalities could be present in otherwise healthy individuals, and their absence does not exclude the diagnosis of epilepsy. Video-EEG monitoring is the standard test for classifying the type of seizure or syndrome or to diagnose pseudoseizures (ie, to establish a definitive diagnosis of spells with impairment of consciousness). This technique is also used to characterize the type of seizure and epileptic syndrome to optimize pharmacologic treatment and for presurgical workup. See Workup for more detail.
Management
Pharmacotherapy The goal of treatment is to achieve a seizure-free status without adverse effects. Monotherapy is important, because it decreases the likelihood of adverse effects and avoids drug interactions. Standard of care for a single, unprovoked seizure is avoidance of typical precipitants (eg, alcohol, sleep deprivation). No anticonvulsants are recommended unless the patient has risk factors for recurrence. Special situations that require treatment include the following: Recurrent unprovoked seizures: The mainstay of therapy is an anticonvulsant; if a patient has had more than 1 seizure, administration of an anticonvulsant is recommended Having an abnormal sleep-deprived EEG that includes epileptiform abnormalities and focal slowing, diffuse background slowing, and intermittent diffuse intermixed slowing Selection of an anticonvulsant medication depends on an accurate diagnosis of the epileptic syndrome. Although some anticonvulsants (eg, lamotrigine, topiramate, valproic acid, zonisamide) have multiple mechanisms of action, and some (eg, phenytoin, carbamazepine, ethosuximide) have only one known mechanism of action, anticonvulsant agents can be divided into large groups based on their mechanisms, as follows: Blockers of repetitive activation of the sodium channel: Phenytoin, carbamazepine, oxcarbazepine,
lamotrigine, topiramate Enhancer of slow inactivation of the sodium channel: Lacosamide, rufinamide Gamma aminobutyric acid (GABA)A receptor enhancers: Phenobarbital, benzodiazepines, clobazam NMDA receptor blockers: Felbamate AMPA receptor blockers: Perampanel, topiramate T-calcium channel blockers: Ethosuximide, valproate N- and L-calcium channel blockers: Lamotrigine, topiramate, zonisamide, valproate H-current modulators: Gabapentin, lamotrigine Blockers of unique binding sites: Gabapentin, levetiracetam Carbonic anhydrase inhibitors: Topiramate, zonisamide Neuronal potassium channel (KCNQ [Kv7]) opener: Ezogabine Nonpharmacologic therapy The following are 2 nonpharmacologic methods in managing patients with seizures: A ketogenic diet Vagal nerve stimulation Surgical options The 2 major kinds of brain surgery for epilepsy are palliative and potentially curative. The use of a vagal nerve stimulator (VNS) for palliative therapy in patients with intractable atonic seizures has reduced the need for anterior callosotomy. Lobectomy and lesionectomy are among several possible curative surgeries. See Treatment and Medication for more detail.
Background
Epileptic seizures are only one manifestation of neurologic or metabolic diseases. Epileptic seizures have many causes, including a genetic predisposition for certain types of seizures, head trauma, stroke, brain tumors, alcohol or drug withdrawal, repeated episodes of metabolic insults, such as hypoglycemia, and other conditions. Epilepsy is a medical disorder marked by recurrent, unprovoked seizures. Therefore, repeated seizures with an identified provocation (eg, alcohol withdrawal) do not constitute epilepsy. As proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) in 2005, epilepsy is defined as a brain disorder characterized by an enduring predisposition to generate epileptic seizures and by the neurobiologic, cognitive, psychological, and social consequences of this condition.[1] Traditionally, the diagnosis of epilepsy requires the occurrence of at least 2 unprovoked seizures. Some clinicians also diagnose epilepsy when 1 unprovoked seizure occurs in the setting of a predisposing cause, such as a focal cortical injury, or a generalized interictal discharge occurs that suggests a persistent genetic predisposition. (See Clinical Presentation.) Seizures are the manifestation of abnormal hypersynchronous or hyperexcitable discharges of cortical neurons. The clinical signs or symptoms of seizures depend on the location of the epileptic discharges in the cerebral cortex and the extent and pattern of the propagation of the epileptic discharge in the brain. Thus, seizure symptoms are highly variable, but for most patients with 1 focus, the symptoms are usually very stereotypic. It should not be surprising that seizures are a common, nonspecific manifestation of neurologic injury and disease, because the main function of the brain is the transmission of electrical impulses. The lifetime likelihood of experiencing at least 1 epileptic seizure is about 9%, and the lifetime likelihood of receiving a diagnosis of epilepsy is almost 3%. However, the prevalence of active epilepsy is only about 0.8%. (See Epidemiology.) This article reviews the classifications, pathophysiology, clinical manifestations, and treatment of epileptic seizures and some common epileptic syndromes. (See Pathophysiology, Presentation, DDx, and Treatment.) For more information regarding seizure types and other conditions, see the following topics:
Absence Seizures Complex Partial Seizures Generalized Tonic-Clonic Seizures Psychogenic Nonepileptic Seizures Pediatric First Seizure Epilepsia Partialis Continua Status Epilepticus Preeclampsia Eclampsia See the following articles for more information regarding epileptic syndromes and epilepsy treatment: Benign Childhood Epilepsy Benign Neonatal Convulsions EEG in Common Epilepsy Syndromes Pediatric Febrile Seizures Neonatal Seizures Frontal Lobe Epilepsy Temporal Lobe Epilepsy Juvenile Myoclonic Epilepsy Lennox-Gastaut Syndrome Posttraumatic Epilepsy Reflex Epilepsy Vagus Nerve Stimulation Women's Health and Epilepsy Partial Epilepsies Pediatric Status Epilepticus Myoclonic Epilepsy Beginning in Infancy or Early Childhood
Historical information
Epileptic seizures have been recognized for millennia. One of the earliest descriptions of a secondary generalized tonic-clonic seizure was recorded over 3000 years ago in Mesopotamia. The seizure was attributed to the god of the moon. Epileptic seizures were described in other ancient cultures, including those of China, Egypt, and India. An ancient Egyptian papyrus described a seizure in a man who had previous head trauma. Hippocrates wrote the first book about epilepsy almost 2500 years ago. He rejected ideas regarding the divine etiology of epilepsy and concluded that the cause was excessive phlegm leading to abnormal brain consistency. Hippocratic teachings were forgotten, and divine etiologies again dominated beliefs about epileptic seizures during medieval times. Even at the turn of the 19th century, excessive masturbation was considered a cause of epilepsy. This hypothesis is credited as leading to the use of the first effective anticonvulsant (ie, bromides). Modern investigation of the etiology of epilepsy began with the work of Fritsch, Hitzig, Ferrier, and Caton in the 1870s. These researchers recorded and evoked epileptic seizures in the cerebral cortex of animals. In 1929, Berger discovered that electrical brain signals could be recorded from the human head by using scalp electrodes; this discovery led to the use of electroencephalography (EEG) to study and classify epileptic seizures. Gibbs, Lennox, Penfield, and Jasper further advanced the understanding of epilepsy and developed the system of the 2 major classes of epileptic seizures currently used: localization-related syndromes and generalized-onset syndromes. An excellent historical review of seizures and epilepsy, written by E. Goldensohn, was published in the journal Epilepsia to commemorate the 50th anniversary of the creation of the American Epilepsy Society in 1997. A decade later, another review in Epilepsia discussed the foundation of this professional society.[4]
Pathophysiology
Seizures are paroxysmal manifestations of the electrical properties of the cerebral cortex. A seizure results when
a sudden imbalance occurs between the excitatory and inhibitory forces within the network of cortical neurons in favor of a sudden-onset net excitation. The brain is involved in nearly every bodily function, including the higher cortical functions. If the affected cortical network is in the visual cortex, the clinical manifestations are visual phenomena. Other affected areas of primary cortex give rise to sensory, gustatory, or motor manifestations. The psychic phenomenon of dj-vu occurs when the temporal lobe is involved. The pathophysiology of focal-onset seizures differs from the mechanisms underlying generalized-onset seizures. Overall, cellular excitability is increased, but the mechanisms of synchronization appear to substantially differ between these 2 types of seizure and are therefore discussed separately. For a review, see the epilepsy book of Rho, Sankar, and Cavazos.[5] For a more recent review, see Kramer and Cash.[6]
Decreased inhibition
The release of GABA from the interneuron terminal inhibits the postsynaptic neuron by means of 2 mechanisms: (1) direct induction of an inhibitory postsynaptic potential (IPSP), which a GABA-A chloride current typically mediates, and (2) indirect inhibition of the release of excitatory neurotransmitter in the presynaptic afferent projection, typically with a GABA-B potassium current. Alterations or mutations in the different chloride or potassium channel subunits or in the molecules that regulate their function may affect the seizure threshold or the propensity for recurrent seizures. Mechanisms leading to decreased inhibition include the following:
Defective GABA-A inhibition Defective GABA-B inhibition Defective activation of GABA neurons Defective intracellular buffering of calcium Normal GABA-A inhibitory function GABA is the main inhibitory neurotransmitter in the brain, and it binds primarily to 2 major classes of receptors: GABA-A and GABA-B. GABA-A receptors are coupled to chloride (negative anion) channels, and they are one of the main targets modulated by the anticonvulsant agents that are currently in clinical use. The reversal potential of chloride is about negative 70 mV. The contribution of chloride channels during resting potential in neurons is minimal, because the typical resting potential is near -70 mV, and thus there is no significant electromotive force for net chloride flux. However, chloride currents become more important at more depolarized membrane potentials. These channels make it difficult to achieve the threshold membrane potential necessary for an action potential. The influence of chloride currents on the neuronal membrane potential increases as the neuron becomes more depolarized by the summation of the excitatory postsynaptic potentials (EPSPs). In this manner, the chloride currents become another force that must be overcome to fire an action potential, decreasing excitability. Properties of the chloride channels associated with the GABA-A receptor are often clinically modulated by using benzodiazepines (eg, diazepam, lorazepam, clonazepam), barbiturates (eg, phenobarbital, pentobarbital), or topiramate. Benzodiazepines increase the frequency of openings of chloride channels, whereas barbiturates increase the duration of openings of these channels. Topiramate also increases the frequency of channel openings, but it binds to a site different from the benzodiazepine-receptor site. Alterations in the normal state of the chloride channels may increase the membrane permeability and conductance of chloride ions. In the end, the behavior of all individual chloride channels sum up to form a large chloride-mediated hyperpolarizing current that counterbalances the depolarizing currents created by the summation of EPSPs induced by activation of the excitatory input. The EPSPs are the main form of communication between neurons, and the release of the excitatory amino acid glutamate from the presynaptic element mediates EPSPs. Three main receptors mediate the effect of glutamate in the postsynaptic neuron: N -methyl-D-aspartic acid (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)/kainate, and metabotropic. These are coupled by means of different mechanisms to several depolarizing channels. IPSPs temper the effects of EPSPs. IPSPs are mediated mainly by the release of GABA in the synaptic cleft with postsynaptic activation of GABA-A receptors. All channels in the nervous system are subject to modulation by several mechanisms, such as phosphorylation and, possibly, a change in the tridimensional conformation of a protein in the channel. The chloride channel has several phosphorylation sites, one of which topiramate appears to modulate. Phosphorylation of this channel induces a change in normal electrophysiologic behavior, with an increased frequency of channel openings but for only certain chloride channels. Each channel has a multimeric structure with several subunits of different types. Chloride channels are no exception; they have a pentameric structure. The subunits are made up of molecularly related but different proteins. The heterogeneity of electrophysiologic responses of different GABA-A receptors results from different combinations of the subunits. In mammals, at least 6 alpha subunits and 3 beta and gamma subunits exist for the GABA-A receptor complex. A complete GABA-A receptor complex (which, in this case, is the chloride channel itself) is formed from 1 gamma, 2 alpha, and 2 beta subunits. The number of possible combinations of the known subunits is almost 1000, but in practice, only about 20 of these combinations have been found in the normal mammalian brain. Defective GABA-A inhibition
Some epilepsies may involve mutations or lack of expression of the different GABA-A receptor complex subunits, the molecules that govern their assembly, or the molecules that modulate their electrical properties. For example, hippocampal pyramidal neurons may not be able to assemble alpha 5 beta 3 gamma 3 receptors because of deletion of chromosome 15 (ie, Angelman syndrome). Changes in the distribution of subunits of the GABA-A receptor complex have been demonstrated in several animal models of focal-onset epilepsy, such as the electrical-kindling, chemical-kindling, and pilocarpine models. In the pilocarpine model, decreased concentrations of mRNA for the alpha 5 subunit of the surviving interneurons were observed in the CA1 region of the rat hippocampus.[7] Defective GABA-B inhibition The GABA-B receptor is coupled to potassium channels, forming a current that has a relatively long duration of action compared with the chloride current evoked by activation of the GABA-A receptor. Because of the long duration of action, alterations in the GABA-B receptor are thought to possibly play a major role in the transition between the interictal abnormality and an ictal event (ie, focal-onset seizure). The molecular structure of the GABA-B receptor complex consists of 2 subunits with 7 transmembrane domains each. G proteins, a second messenger system, mediate coupling to the potassium channel, explaining the latency and long duration of the response. In many cases, GABA-B receptors are located in the presynaptic element of an excitatory projection.
Defective intracellular buffering of calcium In rodents, recurrent seizures induced by a variety of methods result in a pattern of interneuron loss in the hilar polymorphic region, with striking loss of the neurons that lack the calcium-binding proteins parvalbumin and calbindin. In rat hippocampal sections, these interneurons demonstrate a progressive inability to maintain a hyperpolarized resting membrane potential; eventually, the interneurons die. In an experiment, researchers used microelectrodes containing the calcium chelator BAPTA and demonstrated reversal of the deterioration in the membrane potential as the calcium chelator was allowed to diffuse in the interneuron.[9] These findings showed the critical role of adequate concentrations of calcium-binding proteins for neuronal survival in settings with sustained rises of intracellular calcium, such as in status epilepticus and other brain insults. This mechanism may contribute to medical intractability in some epilepsy patients. The vulnerability of interneurons to hypoxia and other insults also correlates to the relative presence of these calcium-binding proteins. The premature loss of interneurons alters inhibitory control over the local neuronal network in favor of net excitation. This effect may explain, for example, why 2 patients who have a similar event (ie, simple febrile convulsion) may have remarkably dissimilar outcomes; that is, one may have completely normal development, and the other may have intractable focal-onset epilepsy after a few years.
Increased activation
Mechanisms leading to increased excitation include the following: Increased activation of NMDA receptors Increased synchrony between neurons due to ephaptic interactions Increased synchrony and/or activation due to recurrent excitatory collaterals Increased activation of NMDA receptors Glutamate is the major excitatory neurotransmitter in the brain. The release of glutamate causes an EPSP in the postsynaptic neuron by activating the glutaminergic receptors AMPA/kainate and NMDA and the metabotropic receptor. Fast neurotransmission is achieved with the activation of the first 2 types of receptors. The metabotropic receptor alters cellular excitability by means of a second-messenger system with later onset but a prolonged duration. The major functional difference between the 2 fast receptors is that the AMPA/kainate receptor opens channels that primarily allow the passage of monovalent cations (ie, sodium and potassium), whereas the NMDA type is coupled to channels that also allow passage of divalent cations (ie, calcium). Calcium is a catalyst for many intracellular reactions that lead to changes in phosphorylation and gene expression. Thus, it is in itself a second-messenger system. NMDA receptors are generally assumed to be associated with learning and memory. The activation of NMDA receptors is increased in several animal models of epilepsy, such as kindling, kainic acid, pilocarpine, and other focal-onset epilepsy models. Some patients with epilepsy may have an inherited predisposition for fast or long-lasting activation of NMDA channels that alters their seizure threshold. Other possible alterations include the ability of intracellular proteins to buffer calcium, increasing the vulnerability of neurons to any kind of injury that otherwise would not result in neuronal death. Increased synchrony between neurons caused by ephaptic interactions Electrical fields created by synchronous activation of pyramidal neurons in laminar structures, such as the hippocampus, may increase further the excitability of neighboring neurons by nonsynaptic (ie, ephaptic) interactions. Changes in extracellular ionic concentrations of potassium and calcium are another possible nonsynaptic interaction, as is increased coupling of neurons due to permanent increases in the functional availability of gap junctions. This last may be a mechanism that predisposes to seizures or status epilepticus. Increased synchrony and/or activation from recurrent excitatory collaterals Neuropathologic studies of patients with intractable focal-onset epilepsy have revealed frequent abnormalities in
the limbic system, particularly in the hippocampal formation. A common lesion is hippocampal sclerosis, which consists of a pattern of gliosis and neuronal loss primarily affecting the hilar polymorphic region and the CA1 pyramidal region. These changes are associated with relative sparing of the CA2 pyramidal region and an intermediate severity of the lesion in the CA3 pyramidal region and dentate granule neurons. Prominent hippocampal sclerosis is found in about two thirds of patients with intractable temporal-lobe epilepsy. Animal models of status epilepticus have reproduced this pattern of injury; however, animals with more than 100 brief convulsions induced by kindling seizures had a similar pattern, suggesting that repeated temporal lobe seizures may contribute to the development of hippocampal sclerosis.[10] More subtle and apparently more common than overt hippocampal sclerosis is mossy-fiber sprouting.[11] The mossy fibers are the axons of the dentate granule neurons, and they typically project into the hilar polymorphic region and toward the CA3 pyramidal neurons. As the neurons in the hilar polymorphic region are progressively lost, their synaptic projections to the dentate granule neurons degenerate. Denervation resulting from loss of the hilar projection induces sprouting of the neighboring mossy fiber axons. The net consequence of this phenomenon is the formation of recurrent excitatory collaterals, which increase the net excitatory drive of dentate granule neurons. Recurrent excitatory collaterals have been demonstrated in human temporal lobe epilepsy and in all animal models of intractable focal-onset epilepsy. The effect of mossy-fiber sprouting on the hippocampal circuitry has been confirmed in computerized models of the epileptic hippocampus. Other neural pathways in the hippocampus, such as the projection from CA1 to the subiculum, have been shown to also remodel in the epileptic brain. For further reading, a review by Mastrangelo and Leuzzi addresses how genes lead to an epileptic phenotype for the early age encephalopathies.[12]
Findings in several animal models of absence seizures, such as lethargic mice, have demonstrated that GABA-B receptor antagonists suppress absence seizures, whereas GABA-B agonists worsen these seizures.[14] Anticonvulsants that prevent absence seizures, such as valproic acid and ethosuximide, suppress the T-calcium current, blocking its channels. A clinical problem is that some anticonvulsants that increase GABA levels (eg, tiagabine, vigabatrin) are associated with an exacerbation of absence seizures. An increased GABA level is thought to increase the degree of synchronization of the thalamocortical circuit and to enlarge the pool of T-calcium channels available for activation.
Etiology
In a substantial number of cases, the cause of epilepsy remains unknown. Identified causes tend to vary with patient age. Inherited syndromes, congenital brain malformations, infection, and head trauma are leading causes in children. Head trauma is the most common known cause in young adults. Strokes, tumors, and head trauma become more frequent in middle age, with stroke becoming the most common cause in the elderly, along with Alzheimer disease and other degenerative conditions. The genetic contribution to seizure disorders is not completely understood, but at the present time, hundreds of genes have been shown to cause or predispose individuals to seizure disorders of various types. Seizures are frequently seen in patients that are referred to a genetics clinic. In some cases, the seizures are isolated in an otherwise normal child. In many cases, seizures are part of a syndrome that may also include intellectual disability, specific brain malformations, or a host of multiple congenital anomalies. For the sake of brevity and clarity, genetic disorders that can cause seizures will be broken into the following categories: Syndromes in which seizures are common Chromosomal deletion or duplication syndromes that cause seizures Metabolic diseases Mitochondrial diseases Seizure disorders caused by single-gene mutations
caused by different genes are described. Additionally, although Rett syndrome has generally been described only in female patients (with the supposition that this would be a lethal disease in males), rare cases have been described in males. Patients with Rett syndrome have a normal prenatal and birth history and normal psychomotor development for the first 6 months, followed by deceleration of head growth in most patients, loss of hand skills over the first 2-3 years of life, hand stereotypies, social withdrawal, communication dysfunction, loss of acquired speech, cognitive impairment, and impairment of movement.[15] Seizures are reported in greater than 90% of females with Rett syndrome. Seizures may be of any type, but generalized tonic-clonic and complex partial seizures are the most common.[16] Pitt-Hopk ins syndrome Pitt-Hopkins syndrome is classically caused by mutations in the TCF4 gene, although several forms of PittHopkinslike syndrome have been described. Patients with Pitt-Hopkins syndrome have severe intellectual disability, microcephaly, and little or no speech. They also have an unusual breathing pattern characterized by intermittent hyperventilation followed by periods of apnea. Patients with Pitt-Hopkins also have distinctive facies, which may not be apparent in early childhood. These features include microcephaly with a coarse facial appearance, deeply set eyes, upslanting palpebral fissures, a broad and beaked nasal bridge with a downturned nasal tip, a wide mouth and fleshy lips, and widely spaced teeth. There is also a tendency toward prognathism. Seizures are seen in this syndrome, with one study reporting a frequency of 20%.[17] Earlier studies suggested that around 50% of patients with Pitt-Hopkins have seizures. Tuberous sclerosis Tuberous sclerosis complex is caused by mutations in the TSC1 or TSC2 genes. Major features of this disease include the following[18] : Facial angiofibromata Ungual or periungual fibromas Hypopigmented macules Connective tissue nevi Retinal hamartomas Cortical tubers Subependymal nodules or giant cell astrocytomas Cardiac rhabdomyomas Lymphangiomyomatosis Renal angiomyolipomas Minor features include the following: Dental enamel pits Rectal hamartomas Bone cysts Cerebral white matter migration lines Gingival fibromas Nonrenal hamartomas Retinal achromic patches Confetti skin lesions Renal cysts A definite diagnosis of tuberous sclerosis requires 2 major features or 1 major and 2 minor features. A probable diagnosis of tuberous sclerosis requires 1 major and 1 minor feature. More than 80% of patients with tuberous sclerosis are reported to have seizures, although this may be an
overestimate. However, this diagnosis should always be strongly considered in the case of infantile spasms. Prader-Willi syndrome Prader-Willi syndrome is most frequently (70%) caused by a deletion in the paternal inherited portion of chromosome 15q11.2-q13. The remainder of cases are caused by maternal uniparental disomy of chromosome 15, complex chromosomal rearrangements, or defects in specific imprinting centers. Patients with Prader-Willi syndrome have neonatal hypotonia and failure to thrive during infancy. Patients have hyperphagia, and onset of weight gain occurs between age 1 and 6 years. Affected individuals also have mildmoderate intellectual impairment, hypogonadism, and characteristic facies consisting of a narrow bifrontal diameter, almond-shaped eyes, a round face, and downturned corners of the mouth. Hands and feet will tend to be small for size. Seizures occur in approximately 10-20% of patients. Sturge-Weber syndrome Sturge-Weber syndrome has an unknown cause and appears to occur in a sporadic fashion. This disorder is characterized by intracranial vascular anomalies called arteriovenous malformations and port-wine stains on the face. Patients with Sturge-Weber syndrome also have seizures and glaucoma. The seizures can be very difficult to control in some of these patients.
Mitochondrial diseases
Mitochondrial disorders are underdiagnosed but often involve seizures and other neurologic manifestations. Mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS) syndrome is a mitochondrial disorder that is associated with seizures; often, seizures are the presenting manifestation. Patients can also have recurrent headache and vomiting. Myoclonic epilepsy with ragged red fibers (MERRF) is characterized by myoclonus, seizures, and ataxia; myopathy, hearing loss, and vision loss can also occur. Genetic tests are available for these disorders.
Epidemiology
Hauser and collaborators demonstrated that the annual incidence of recurrent nonfebrile seizures in Olmsted County, Minnesota, was about 100 cases per 100,000 persons aged 0-1 year, 40 per 100,000 persons aged 39-40 years, and 140 per 100,000 persons aged 79-80 years. By the age of 75 years, the cumulative incidence of epilepsy is 3400 per 100,000 men (3.4%) and 2800 per 100,000 women (2.8%).[22] Studies in several developed countries have shown incidences and prevalences of seizures similar to those in the United States. In some countries, parasitic infections account for an increased incidence of epilepsy and seizures.
Prognosis
The patient's prognosis for disability and for a recurrence of epileptic seizures depends on the type of epileptic seizure and the epileptic syndrome in question. Impairment of consciousness during a seizure may unpredictably result in morbidity or even mortality. Regarding morbidity, trauma is not uncommon among people with generalized tonic-clonic seizures. Injuries such as ecchymosis; hematomas; abrasions; tongue, facial, and limb lacerations; and even shoulder dislocation can develop as a result of the repeated tonic-clonic movements. Atonic seizures are also frequently associated with
facial injuries, as well as injuries to the neck. Worldwide, burns are the most common serious injury associated with epileptic seizures.
SUDEP
Regarding mortality, seizures cause death in a small proportion of individuals. Most deaths are accidental and result from impaired consciousness. However, sudden, unexpected death in epilepsy (SUDEP) is a risk in persons with epilepsy, and it may occur even when patients are resting in a protected environment (ie, in a bed with rail guards or in the hospital). The incidence of SUDEP is low, about 2.3 times higher than the incidence of sudden death in the general population. The increased risk of death is seen mostly in people with long-standing focal-onset epilepsy, but it is also present in individuals with primary generalized epilepsy. The risk of SUDEP increases in the setting of uncontrolled seizures and in people with poor medication compliance. The risk increases further in people with uncontrolled secondary generalized tonic-clonic seizures. The mechanism of death in SUDEP is controversial, but suggestions include cardiac arrhythmias, neurogenic pulmonary edema, and suffocation during an epileptic seizure with impairment of consciousness. Treatment with anticonvulsants decreases the likelihood of an accidental seizure-related death, and successful epilepsy surgery decreases the risk of SUDEP to that of the general population. In 2011, the National Institutes of Health (NIH) convened a workshop on SUDEP to focus research efforts and to determine benchmarks for further study.[23] A summary of their report can be found at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3115809/.
Patient Education
To prevent injury, provide education about seizure precautions to patients who have lapses of consciousness during wakefulness and in whom seizures are suspected. Most accidents occur when patients have impaired consciousness. This is one of the reasons for restrictions on driving, swimming, taking unsupervised baths, working at significant heights, and the use of fire and power tools for people who have epileptic seizures and other spells of sudden-onset seizures. The restrictions differ for each patient because of the individual features of the seizures, the degree of seizure control, and, in the United States, state laws. Other countries have more permissive or more restrictive laws regarding driving. Check state driving laws before making recommendations. Epilepsy Foundation of America has a large library of educational materials that are available to healthcare professionals and the general public. The American Epilepsy Society is a professional organization for people who take care of patients with epilepsy. Their Website provides a large amount of credible information. For patient education information, see the Brain and Nervous System Center, as well as Epilepsy and Seizures Emergencies.
and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association Disclosure: UCB Pharma Honoraria Speaking, consulting; Lundbeck Honoraria Speaking, consulting; Cyberonics Honoraria Speaking, consulting; Glaxo Smith Kline Honoraria Speaking, consulting; Sleepmed/DigiTrace Honoraria Speaking, consulting; Sunovion Consulting fee None Additional Contributors Jose E Cavazos, MD, PhD, FAAN, FANA, FACNS Professor with Tenure, Departments of Neurology, Pharmacology, and Physiology, Assistant Dean for the MD/PhD Program, Program Director of the Clinical Neurophysiology Fellowship, University of Texas School of Medicine at San Antonio; Co-Director, South Texas Comprehensive Epilepsy Center, University Hospital System; Director, San Antonio Veterans Affairs Epilepsy Center of Excellence and Neurodiagnostic Centers, Audie L Murphy Veterans Affairs Medical Center Jose E Cavazos, MD, PhD, FAAN, FANA, FACNS is a member of the following medical societies: American Academy of Neurology, American Clinical Neurophysiology Society, American Epilepsy Society, American Neurological Association, and Society for Neuroscience Disclosure: LGCH, Inc Ownership interest Consulting Ramon Diaz-Arrastia, MD, PhD Professor, Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Southwestern Medical School; Director, North Texas TBI Research Center, Comprehensive Epilepsy Center, Parkland Memorial Hospital Ramon Diaz-Arrastia, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, New York Academy of Sciences, and Phi Beta Kappa Disclosure: Nothing to disclose. Mark Spitz, MD Professor, Department of Neurology, University of Colorado Health Sciences Center Mark Spitz, MD is a member of the following medical societies: American Academy of Neurology, American Clinical Neurophysiology Society, and American Epilepsy Society Disclosure: pfizer Honoraria Speaking and teaching; ucb Honoraria Speaking and teaching; lumdbeck Honoraria Consulting Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference Disclosure: Medscape Salary Employment
References
1. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. Apr 2005;46(4):470-2. [Medline]. 2. Iorio R, Assenza G, Della Marca G, et al. Neural autoantibodies and immunotherapy-responsive epilepsy: a prospective study [abstract 1956]. Presented at: XXI World Congress of Neurology (WNC), 2013; September 22, 2013; Vienna, Austria. [Full Text]. 3. Keller DM. Immunotherapy helps epileptic patients with neural antibodies. Medscape Medical News [serial online]. September 27, 2013;Accessed October 7, 2013. Available at http://www.medscape.com/viewarticle/811804. 4. Goodkin HP. The founding of the American Epilepsy Society: 1936-1971. Epilepsia. Jan 2007;48(1):15-22.
[Medline]. 5. Rho JM, Sankar R, Cavazos JE. Epilepsy: Scientific Foundations of Clinical Practice. New York, NY: Marcel Dekker; 2004. 6. Kramer MA, Cash SS. Epilepsy as a disorder of cortical network organization. Neuroscientist. Aug 2012;18(4):360-72. [Medline]. 7. Houser CR, Esclapez M. Vulnerability and plasticity of the GABA system in the pilocarpine model of spontaneous recurrent seizures. Epilepsy Res . Dec 1996;26(1):207-18. [Medline]. 8. Sloviter RS. Status epilepticus-induced neuronal injury and network reorganization. Epilepsia. 1999;40(suppl 1):S34-9; discussion S40-1. [Medline]. 9. Scharfman HE, Schwartzkroin PA. Protection of dentate hilar cells from prolonged stimulation by intracellular calcium chelation. Science. Oct 13 1989;246(4927):257-60. [Medline]. 10. Cavazos JE, Das I, Sutula TP. Neuronal loss induced in limbic pathways by kindling: evidence for induction of hippocampal sclerosis by repeated brief seizures. J Neurosci. May 1994;14(5 pt 2):3106-21. [Medline]. 11. Sutula T, Cascino G, Cavazos J, et al. Mossy fiber synaptic reorganization in the epileptic human temporal lobe. Ann Neurol. Sep 1989;26(3):321-30. [Medline]. 12. Mastrangelo M, Leuzzi V. Genes of early-onset epileptic encephalopathies: from genotype to phenotype. Pediatr Neurol. Jan 2012;46(1):24-31. [Medline]. 13. McCormick DA. Cellular mechanisms underlying cholinergic and noradrenergic modulation of neuronal firing mode in the cat and guinea pig dorsal lateral geniculate nucleus. J Neurosci. Jan 1992;12(1):278-89. [Medline]. 14. Hosford DA, Clark S, Cao Z, et al. The role of GABAB receptor activation in absence seizures of lethargic (lh/lh) mice. Science. Jul 17 1992;257(5068):398-401. [Medline]. 15. Hagberg B, Hanefeld F, Percy A, Skjeldal O. An update on clinically applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden Baden, Germany, 11 September 2001. Eur J Paediatr Neurol. 2002;6(5):293-7. [Medline]. 16. Steffenburg U, Hagberg G, Hagberg B. Epilepsy in a representative series of Rett syndrome. Acta Paediatr. Jan 2001;90(1):34-9. [Medline]. 17. Whalen S, Hron D, Gaillon T, Moldovan O, Rossi M, Devillard F, et al. Novel comprehensive diagnostic strategy in Pitt-Hopkins syndrome: clinical score and further delineation of the TCF4 mutational spectrum. Hum Mutat. Jan 2012;33(1):64-72. [Medline]. 18. Roach ES, Sparagana SP. Diagnosis of tuberous sclerosis complex. J Child Neurol. Sep 2004;19(9):6439. [Medline]. 19. Kao A, Mariani J, McDonald-McGinn DM, Maisenbacher MK, Brooks-Kayal AR, Zackai EH, et al. Increased prevalence of unprovoked seizures in patients with a 22q11.2 deletion. Am J Med Genet A. Aug 15 2004;129A(1):29-34. [Medline]. 20. Battaglia A, Filippi T, South ST, Carey JC. Spectrum of epilepsy and electroencephalogram patterns in Wolf-Hirschhorn syndrome: experience with 87 patients. Dev Med Child Neurol. May 2009;51(5):373-80. [Medline]. 21. Battaglia A, Hoyme HE, Dallapiccola B, Zackai E, Hudgins L, McDonald-McGinn D, et al. Further delineation of deletion 1p36 syndrome in 60 patients: a recognizable phenotype and common cause of developmental delay and mental retardation. Pediatrics . Feb 2008;121(2):404-10. [Medline].
22. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of populationbased studies from Rochester, Minnesota. Mayo Clin Proc . Jun 1996;71(6):576-86. [Medline]. 23. [Best Evidence] Hirsch LJ, Donner EJ, So EL, Jacobs M, Nashef L, Noebels JL, et al. Abbreviated report of the NIH/NINDS workshop on sudden unexpected death in epilepsy. Neurology. May 31 2011;76(22):1932-8. [Medline]. [Full Text]. 24. Luders H, Acharya J, Baumgartner C, et al. Semiological seizure classification. Epilepsia. Sep 1998;39(9):1006-13. [Medline]. 25. Loddenkemper T, Kellinghaus C, Wyllie E, Najm IM, Gupta A, Rosenow F. A proposal for a fivedimensional patient-oriented epilepsy classification. Epileptic Disord. Dec 2005;7(4):308-16. [Medline]. 26. Engel J Jr. Report of the ILAE classification core group. Epilepsia. Sep 2006;47(9):1558-68. [Medline]. 27. Wolf P. Basic principles of the ILAE syndrome classification. Epilepsy Res . Aug 2006;70 suppl 1:S20-6. [Medline]. 28. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. Apr 2010;51(4):676-85. [Medline]. 29. Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia. Jun 2001;42(6):796-803. [Medline]. 30. Wolf P. Of cabbages and kings: some considerations on classifications, diagnostic schemes, semiology, and concepts. Epilepsia. Jan 2003;44(1):1-4; discussion 4-13. [Medline]. 31. Beghi E. The concept of the epilepsy syndrome: how useful is it in clinical practice?. Epilepsia. May 2009;50 suppl 5:4-10. [Medline]. 32. [Guideline] Chen DK, So YT, Fisher RS. Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. Sep 13 2005;65(5):668-75. [Medline]. 33. First Seizure Trial Group (FIR.S.T Group). Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. Neurology. Mar 1993;43(3 pt 1):478-83. [Medline]. 34. [Best Evidence] Glauser TA, Cnaan A, Shinnar S, et al, for the Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. Mar 4 2010;362(9):790-9. [Medline]. 35. Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. Oct 11 2011;77(15):1473-1481. [Medline]. 36. [Best Evidence] Marson AG, Al-Kharusi AM, Alwaidh M, et al, for the SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. Mar 24 2007;369(9566):1016-26. [Medline]. 37. US Food and Drug Administration. FDA approves Fycompa to treat seizures. October 22, 2012. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm325038.htm. Accessed Sept 19, 2013. 38. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. Jul 18 1985;313(3):145-51. [Medline]. 39. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med. Sep 10 1992;327(11):765-71.
[Medline]. 40. [Best Evidence] Rowan AJ, Ramsay RE, Collins JF, et al, for the VA Cooperative Study 428 Group. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. Jun 14 2005;64(11):1868-73. [Medline]. 41. [Best Evidence] Marson AG, Al-Kharusi AM, Alwaidh M, et al, for the SANAD Study Group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. Mar 24 2007;369(9566):1000-15. [Medline]. 42. French JA, Kanner AM, Bautista J, et al, for the Therapeutics and Technology Assessment Subcommittee of the AAN; Quality Standards Subcommittee of the AAN; and AES. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. Apr 27 2004;62(8):1252-60. [Medline]. 43. French JA, Kanner AM, Bautista J, et al for the Therapeutics and Technology Assessment Subcommittee of the AAN; Quality Standards Subcommittee of the AAN; and AES. Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. Apr 27 2004;62(8):1261-73. [Medline]. 44. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. Jun 2010;51(6):1069-77. [Medline]. 45. Ramos-Lizana J, Rodriguez-Lucenilla MI, Aguilera-Lpez P, Aguirre-Rodrguez J, Cassinello-Garca E. A study of drug-resistant childhood epilepsy testing the new ILAE criteria. Seizure. May 2012;21(4):266-72. [Medline]. 46. [Guideline] Harden CL, Pennell PB, Koppel BS, et al, for the AAN and AES. Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. May 2009;50(5):1247-55. [Medline]. 47. [Guideline] Birbeck GL, French JA, Perucca E, Simpson DM, Fraimow H, George JM, et al. Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia. Jan 2012;53(1):207-14. [Medline]. 48. [Guideline] Harden CL, Hopp J, Ting TY, et al, for the AAN and AES. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. May 2009;50(5):1229-36. [Medline]. 49. [Guideline] Harden CL, Meador KJ, Pennell PB, et al, for the AAN and AES. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. May 2009;50(5):1237-46. [Medline]. 50. Levy RG, Cooper PN, Giri P. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev. Mar 14 2012;3:CD001903. [Medline]. 51. Kossoff EH, Turner Z, Bluml RM, Pyzik PL, Vining EP. A randomized, crossover comparison of daily carbohydrate limits using the modified Atkins diet. Epilepsy Behav. May 2007;10(3):432-6. [Medline]. 52. Weber S, Mlgaard C, Karentaudorf, Uldall P. Modified Atkins diet to children and adolescents with
medical intractable epilepsy. Seizure. May 2009;18(4):237-40. [Medline]. 53. Smith M, Politzer N, Macgarvie D, McAndrews MP, Del Campo M. Efficacy and tolerability of the modified Atkins diet in adults with pharmacoresistant epilepsy: a prospective observational study. Epilepsia. Apr 2011;52(4):775-80. [Medline]. 54. Anderson P. FDA approves extended-release once-daily epilepsy drug. Medscape Medical News [serial online]. August 21, 2013;Accessed August 27, 2013. Available at http://www.medscape.com/viewarticle/809719. 55. Supernus Pharmaceuticals, Inc. Supernus announces final FDA approval and upcoming launch of Trokendi XR(TM) [press release]. August 19, 2013. Available at http://ir.supernus.com/releasedetail.cfm? ReleaseID=785927. Accessed August 27, 2013. 56. Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. J Neurosurg. Dec 2011;115(6):1248-55. [Medline]. 57. Anderson P. FDA Panel Endorses Epilepsy Neurostimulator. Medscape Medical News. Available at http://www.medscape.com/viewarticle/779901. Accessed March 4, 2013. 58. [Best Evidence] Wiebe S, Blume WT, Girvin JP, Eliasziw M, for the Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporallobe epilepsy. N Engl J Med. Aug 2 2001;345(5):311-8. [Medline]. 59. Hyslop A, Miller I, Bhatia S, Jayakar P. Functional lesionectomy: a minimally resective strategy effective in children with MRI-negative, intractable epilepsy [abstract 1.280]. Presented at: 66th Annual Meeting of the American Epilepsy Society; December 1, 2012; San Diego, Calif. 60. Melville NA. Minimal resection effective for some patients with epilepsy. Medscape Medical News. January 3, 2013;Accessed January 15, 2013. Available at http://www.medscape.com/viewarticle/777048. 61. Engel J Jr, McDermott MP, Wiebe S, Langfitt JT, Stern JM, Dewar S, et al. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA. Mar 7 2012;307(9):922-30. [Medline]. 62. Herman AO. Anti-seizure drug linked to retinal abnormalities, skin discoloration. Physician's First Watch [serial online]. April 29, 2013;Accessed May 7, 2013. Available at http://firstwatch.jwatch.org/cgi/content/full/2013/429/2. Medscape Reference 2011 WebMD, LLC